mTOR pathway alterations in chromophobe renal cell carcinoma: Impact on metastasis development and overall survival

Autor: Rocío Letón, María Monteagudo, Guillermo Velasco, Cristina Montero-Conde, Alberto Cascón, Cristina Rodríguez-Antona, Bruna Calsina, Eduardo Caleiras, Georgia Anguera, Jose Maria Roldan, Pablo Maroto, A. Martinez, Jesús García-Donas, Javier Lanillos, Mercedes Robledo, Mirentxu Santos, Lj Leandro-Garcia

Publikováno v: Publons

712 Background: Chromophobe renal cell carcinoma (chRCC) is a histologically and molecularly distinct class of rare renal cancer representing less than 5% of the kidney tumors. Molecular knowledge of this disease is limited, as well as prognostic fac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c86043ce10e706adfa712f1341847bb
https://doi.org/10.1200/jco.2020.38.6_suppl.712

Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.

Autor: Luckett KA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Cracchiolo JR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Krishnamoorthy GP; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Leandro-Garcia LJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Nagarajah J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Saqcena M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lester R; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Im SY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Zhao Z; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Sherman EJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill-Cornell Medical College, New York, New York, USA., Ho AL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill-Cornell Medical College, New York, New York, USA., Leach SD; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Knauf JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Fagin JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill-Cornell Medical College, New York, New York, USA.

Publikováno v: Endocrine-related cancer [Endocr Relat Cancer] 2021 May 18; Vol. 28 (6), pp. 391-402. Date of Electronic Publication: 2021 May 18.

Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.

Autor: Montero-Conde C; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center, Madrid, Spain 28029., Leandro-Garcia LJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Chen X; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Oler G; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Ruiz-Llorente S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Ryder M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Landa I; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Sanchez-Vega F; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065., La K; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Ghossein RA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Bajorin DF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Knauf JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Riordan JD; Department of Anatomy and Cell Biology, University of Iowa, Iowa City, IA 52242., Dupuy AJ; Department of Anatomy and Cell Biology, University of Iowa, Iowa City, IA 52242., Fagin JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065; faginj@mskcc.org.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2017 Jun 20; Vol. 114 (25), pp. E4951-E4960. Date of Electronic Publication: 2017 Jun 05.